Used in pharmaceutical research as a potent inhibitor of receptor tyrosine kinases, particularly targeting pathways involved in cancer cell proliferation and angiogenesis. Demonstrates strong activity in suppressing tumor growth in preclinical models, especially in solid tumors such as lung, breast, and colon cancers. Its structure enables high selectivity and improved pharmacokinetic properties, making it a candidate for targeted cancer therapy development. Also investigated for overcoming resistance to existing kinase inhibitors due to its unique binding mechanism. Currently utilized in experimental studies to evaluate efficacy, safety, and optimal dosing regimens in oncology.